A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZKLJ02 Injection in Healthy Chinese Research Participants

NCT07638098 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Evaluate the Safety and Tolerability of ZKLJ02 Injection in Healthy Chinese Research Participants

Interventions

DRUG: 10 mg of ZKLJ02 for injection or placebo
DRUG: 20 mg of ZKLJ02 for injection or placebo
DRUG: 40 mg of ZKLJ02 for injection or placebo
DRUG: 80 mg of ZKLJ02 for injection or placebo
DRUG: 120 mg of ZKLJ02 for injection or placebo

Sponsor

Yunnan Zhongke Longjin Biotechnology Co.,Ltd.